Investigating how chromium exposure affects lung cancer development
METTL3 in chromium-induced angiogenesis and carcinogenesis
['FUNDING_R01'] · THOMAS JEFFERSON UNIVERSITY · NIH-11019705
This study is looking at how a protein called METTL3 might play a part in lung cancer that develops from exposure to a harmful substance called hexavalent chromium, and it’s for anyone interested in understanding how this exposure affects lung cells and cancer growth.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THOMAS JEFFERSON UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11019705 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a specific protein, METTL3, in the development of lung cancer caused by exposure to hexavalent chromium. Researchers will study how chromium influences RNA modifications and the mechanisms that lead to cancerous changes in lung cells. By examining samples from both animal models and human workers exposed to chromium, the study aims to uncover the biological pathways involved in cancer progression and angiogenesis, which is the formation of new blood vessels that support tumor growth.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been exposed to hexavalent chromium, particularly nonsmoking workers in relevant industries.
Not a fit: Patients who have not been exposed to chromium or who have other types of lung cancer unrelated to chromium exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating lung cancer associated with chromium exposure.
How similar studies have performed: While there is emerging interest in the mechanisms of chromium-induced carcinogenesis, this specific approach focusing on METTL3 is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
PHILADELPHIA, UNITED STATES
- THOMAS JEFFERSON UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCMAHON, STEVEN B. — THOMAS JEFFERSON UNIVERSITY
- Study coordinator: MCMAHON, STEVEN B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.